Stock Scorecard



Stock Summary for Compass Therapeutics Inc (CMPX) - $3.08 as of 2/21/2025 3:12:17 PM EST

Total Score

8 out of 30

Safety Score

26 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CMPX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CMPX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CMPX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CMPX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CMPX (26 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for CMPX

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Candel Therapeutics ( NASDAQ:CADL ) , Compass Therapeutics ( NASDAQ:CMPX ) 2/19/2025 3:39:00 PM
Compass Therapeutics, Inc. ( CMPX ) Upgraded to Buy: What Does It Mean for the Stock? 2/10/2025 5:00:00 PM
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why 1/31/2025 4:20:00 PM
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Compass Therapeutics ( NASDAQ:CMPX ) 1/29/2025 1:00:00 PM
Is Compass Therapeutics, Inc. ( CMPX ) Stock Outpacing Its Medical Peers This Year? 12/10/2024 2:40:00 PM
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference 12/2/2024 1:00:00 PM
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - Compass Therapeutics ( NASDAQ:CMPX ) 12/2/2024 1:00:00 PM
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. ( CMPX ) 11/21/2024 2:35:00 PM
What Makes Compass Therapeutics, Inc. ( CMPX ) a New Buy Stock 11/15/2024 5:00:00 PM
Compass Therapeutics to Participate in Upcoming Investor Events 11/13/2024 1:30:00 PM

Financial Details for CMPX

Company Overview

Ticker CMPX
Company Name Compass Therapeutics Inc
Country USA
Description Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts.
Sector Name REAL ESTATE & CONSTRUCTION
Industry Name BLANK CHECKS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 3.08
Price 4 Years Ago 3.17
Last Day Price Updated 2/21/2025 3:12:17 PM EST
Last Day Volume 1,125,343
Average Daily Volume 2,345,216
52-Week High 4.08
52-Week Low 0.77
Last Price to 52 Week Low 300.00%

Valuation Measures

Trailing PE N/A
Industry PE 61.41
Sector PE 63.46
5-Year Average PE -6.84
Free Cash Flow Ratio 3.14
Industry Free Cash Flow Ratio 151.90
Sector Free Cash Flow Ratio 106.99
Current Ratio Most Recent Quarter 31.84
Total Cash Per Share 0.98
Book Value Per Share Most Recent Quarter 1.01
Price to Book Ratio 3.36
Industry Price to Book Ratio 8.03
Sector Price to Book Ratio 12.38
Price to Sales Ratio Twelve Trailing Months 498.56
Industry Price to Sales Ratio Twelve Trailing Months 0.69
Sector Price to Sales Ratio Twelve Trailing Months 4.44
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 137,589,000
Market Capitalization 423,774,120
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -8.33%
Reported EPS 12 Trailing Months -0.35
Reported EPS Past Year -0.26
Reported EPS Prior Year -0.34
Net Income Twelve Trailing Months -47,759,000
Net Income Past Year -42,494,000
Net Income Prior Year -39,225,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -6,523.00%

Balance Sheet

Total Cash Most Recent Quarter 135,402,000
Total Cash Past Year 156,255,000
Total Cash Prior Year 152,461,000
Net Cash Position Most Recent Quarter 135,402,000
Net Cash Position Past Year 156,255,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 157,060,000
Total Stockholder Equity Prior Year 148,538,000
Total Stockholder Equity Most Recent Quarter 138,398,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -48,100,000
Free Cash Flow Per Share Twelve Trailing Months -0.35
Free Cash Flow Past Year -40,648,000
Free Cash Flow Prior Year -34,337,000

Options

Put/Call Ratio 11.75
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.29
MACD Signal 0.37
20-Day Bollinger Lower Band 0.67
20-Day Bollinger Middle Band 2.06
20-Day Bollinger Upper Band 3.44
Beta 0.98
RSI 51.57
50-Day SMA 1.69
150-Day SMA 2.43
200-Day SMA 2.73

System

Modified 2/21/2025 9:10:29 PM EST